| Paper | Authors | Journal | Year | Type |
|---|
| Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers | Barroso S et al. | PloS one | 2019 | Randomized Controlled Trial |
| Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial | de Castro N et al. | AIDS research and therapy | 2016 | Randomized Controlled Trial |
| Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity | Tashima KT et al. | HIV clinical trials | 2015 | Clinical Trial |
| Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients | Meng Q et al. | Journal of pharmaceutical sciences | 2014 | Randomized Controlled Trial |
| Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy | Silva EF et al. | The Journal of infectious diseases | 2013 | Randomized Controlled Trial |
| Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173 | Gandhi RT et al. | Antiviral therapy | 2013 | Clinical Trial |
| Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo) | Joly V et al. | Antimicrobial agents and chemotherapy | 2013 | Randomized Controlled Trial |
| Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial | Charpentier C et al. | The Journal of antimicrobial chemotherapy | 2013 | Randomized Controlled Trial |
| Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study | Morand-Joubert L et al. | Journal of medical virology | 2012 | Randomized Controlled Trial |
| Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures | Tsibris AM et al. | Journal of virology | 2012 | Clinical Trial, Phase II |
| Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study | Bonora S et al. | Infection | 2012 | Clinical Trial |
| Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy | Gasnault J et al. | PloS one | 2011 | Clinical Trial |
| Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial | Gallien S et al. | The Journal of antimicrobial chemotherapy | 2011 | Randomized Controlled Trial |
| Two-year safety and tolerability study of enfuvertide use in salvage therapy of Thai HIV-1 experienced cases | Prasithsirikul W et al. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet | 2011 | Clinical Trial |
| The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy | Cooper DA et al. | HIV medicine | 2011 | Randomized Controlled Trial |
| Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138) | Boulet T et al. | HIV clinical trials | 2010 | Randomized Controlled Trial |
| A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s) | Ruane P et al. | AIDS research and human retroviruses | 2010 | Clinical Trial, Phase III |
| Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials | Katlama C et al. | Antiviral therapy | 2010 | Randomized Controlled Trial |
| Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy | Yilmaz A et al. | Journal of acquired immune deficiency syndromes (1999) | 2010 | Randomized Controlled Trial |
| Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection | Archin NM et al. | PloS one | 2010 | Clinical Trial |
| No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy | Gandhi RT et al. | The Journal of infectious diseases | 2010 | Clinical Trial |
| Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme | Loutfy M et al. | The Journal of antimicrobial chemotherapy | 2009 | Clinical Trial |
| Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation | Teicher E et al. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society | 2009 | Clinical Trial |
| Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial | De Castro N et al. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2009 | Randomized Controlled Trial |
| Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study | Towner W et al. | Journal of acquired immune deficiency syndromes (1999) | 2009 | Clinical Trial |
| Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients | Viard JP et al. | AIDS (London, England) | 2009 | Randomized Controlled Trial |
| Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults | Jacobson JM et al. | Antimicrobial agents and chemotherapy | 2009 | Randomized Controlled Trial |
| Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study | Streinu-Cercel A et al. | HIV clinical trials | 2008 | Clinical Trial, Phase IV |
| Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study | DeJesus E et al. | Antimicrobial agents and chemotherapy | 2008 | Clinical Trial |
| A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study | Clotet B et al. | The Journal of antimicrobial chemotherapy | 2008 | Randomized Controlled Trial |